The Food and Drug Administration (FDA) has approved neffy ® (epinephrine nasal spray) 1mg for the emergency treatment of type 1 allergic reactions, including anaphylaxis, in pediatric patients aged 4 ...

The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps ...

Chronic spontaneous urticaria is an idiopathic syndrome defined by recurring itch, hives, or angioedema (or a combination of ...

Phase III REMIX-1 and REMIX-2 trials demonstrated that remibrutinib, an oral BTK inhibitor, significantly reduced chronic ...

The FDA has approved Neffy, a needle-free nasal spray, for children aged 4 and up, providing fast and effective treatment for severe allergic reactions and anaphylaxis.

Injuries to the articular cartilage in different joints, including the knee, are painful and limit mobility. In response, ...